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Abstract
Mutations in CCM1 (aka KRIT1), CCM2, or CCM3 (aka PDCD10) gene cause cerebral cav-
ernous malformation in humans. Mouse models of CCM disease have been established by
deleting Ccm genes in postnatal animals. These mouse models provide invaluable tools to
investigate molecular mechanism and therapeutic approaches for CCM disease. However,
the full value of these animal models is limited by the lack of an accurate and quantitative
method to assess lesion burden and progression. In the present study we have established
a refined and detailed contrast enhanced X-ray micro-CT method to measure CCM lesion
burden in mouse brains. As this study utilized a voxel dimension of 9.5μm (leading to a mini-
mum feature size of approximately 25μm), it is therefore sufficient to measure CCM lesion
volume and number globally and accurately, and provide high-resolution 3-D mapping of
CCM lesions in mouse brains. Using this method, we found loss of Ccm1 orCcm2 in neona-
tal endothelium confers CCM lesions in the mouse hindbrain with similar total volume and
number. This quantitative approach also demonstrated a rescue of CCM lesions with simul-
taneous deletion of one allele ofMekk3. This method would enhance the value of the estab-
lished mouse models to study the molecular basis and potential therapies for CCM and
other cerebrovascular diseases.
Introduction
Cerebral cavernous malformation (CCM) is a brain vascular disease that manifests as clusters
of thin dilated vessels in brain. It is common with a prevalence of 0.1–0.5% in the human popu-
lation. Currently there is no drug treatment available for CCM disease and individual lesions
can only be treated through surgical resection when possible [1]. Human genetic studies have
identified mutations in three genes, CCM1 (aka Krit1), CCM2 and CCM3 (aka PDCD10),
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causing CCM disease [2–6]. These genes encode non-homologous cytoplasmic proteins form-
ing a single signaling complex. Genetic studies in the mouse and zebrafish have revealed that
the CCM pathway functions in endothelial cells and is required for patterning of blood vessels
and the development of embryonic heart [7–11]. In the developing heart, our recent study
revealed that CCM signaling negatively controls the Mekk3 kinase cascade, Klf2 and Klf4
expression and Adamts4 and Adamts5 expression in endocardium. Deletion of Ccm genes in
the endocardium leads to elevated Adamts activity via MEKK3-KLF signaling and causes pre-
mature degradation of cardiac matrix (jelly) and ultimately cardiac growth arrest [10]. Geneti-
cally decreasingMekk3 or Klf2 gene dosage rescues the cardiac defect conferred by Ccm
deficiency both in mice and zebrafish [10].
Various mouse models have been developed to model human CCM disease and investigate
the disease-causing mechanisms downstream of CCM genes [12–15]. Among these, the most
robust model is to delete conditional Ccm genes with Tamoxifen-inducible Cdh5-CreERT2 or
Tie2-CreErt2 at P1 or P2 in newborn pups [13,15]. These pups display severe CCM lesion bur-
den, from P11 onward. These mouse models have been expected to provide an invaluable foun-
dation for pre-clinical studies to search for therapeutic agents in treating CCM diseases.
However, their utility has been limited by the lack of an efficient and accurate method to quan-
tify CCM lesion burden, a situation that has significantly restricted the application of these
mouse models for pre-clinical research.
Until now, CCM lesion burden has been measured primarily using histology-based meth-
ods, an approach that is low through-put, provides an incomplete view of CCM lesions in
brain, and one that is subject to investigator bias [15–17]. MRI based methods have recently
been used by one research group to assess CCM lesion burden in adult mouse model [14,18].
However, a highly specialized small animal MRI instrument is required and a long scan-time
(several hours to overnight) is necessary to achieve a resolution reliably identifying CCM
lesions in adult mice. The ability of MRI to detect CCM lesions in neonatal mice has not been
reported and resolution may limit sensitivity. Thus, a high-resolution, time and cost effective
method is needed to appropriately exploit the value of mouse CCMmodels.
We have adopted a contrast-based micro-CT technique to image CCM lesions in the mouse
model. This method provides quantitative global measurement of CCM lesion volume, accu-
rately identifies the number and 3-D location of CCM lesions in the mouse brain, and greatly
reduces the cost and time required to phenotype these animals. Micro-CT imaging of CCM
lesion in mouse brain therefore provides a novel and more applicable tool to exploit CCM
mouse models for mechanistic or pre-clinical studies of CCM disease. We have recently used
this imaging technique to demonstrateMekk3, Klf2 or klf4 heterozygosity prevents CCM lesion
formation in Ccm1 deficient mice [19]. In this study, we demonstrate the utility of this imaging
approach by comparing the lesions in Ccm1 and Ccm2 deficient mice, and demonstrate that
Mekk3 heterozygosity prevents CCM lesion formation in Ccm2 deficient mice.
Methods
An overview of the process is shown in Fig 1.
Mice
All animal ethics and protocols were approved by The Sydney Local Health District Animal
Welfare Committee. All experiments were conducted under the guidelines/regulations of Cen-
tenary Institute and University of Sydney.
Cdh5-CreErt2, Ccm1fl/fl, Ccm2fl/fl,Mekk3fl/fl animals have been previously described [10,20–
22]. Cdh5-CreErt2;Ccm1fl/+ mice were crossed with Ccm1fl/fl to generate Cdh5-CreErt2;Ccm1fl/fl
Micro-CT Imaging of CCM
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(Ccm1iECKO), Cdh5-CreErt2;Ccm2fl/+mice were crossed with Ccm2fl/fl to generate Cdh5-CreErt2;
Ccm2fl/fl (Ccm2iECKO), and Cdh5-CreErt2;Ccm2fl/flmice were crossed with Ccm2fl/fl;Mekk3fl/+
mice to generate Cdh5-CreErt2;Ccm2fl/fl;Mekk3fl/+ (Ccm2iECKO;Mekk3het). Number of mice used
in each experimental groups are outlined in each results section and figure legends.
CCM lesion induction & Sample preparation
CCM lesion induction. Tamoxifen (TMX) (T5648-1G, Sigma-Aldrich) was dissolved in
100% ethanol and stored at -80°C in aliquots (TMX concentration: 50 mg/ml). On the day of
use, aliquoted TMX was diluted in corn oil (C8267-500ML, Sigma-Aldrich) (4 mg/ml). Neona-
tal pups at postnatal day 1 (P1) were injected intragastrically with 50μl of TMX (4 mg/ml) to
induce experimental CCM lesions using a 30-gauge needle. A single injection of TMX at P1
was sufficient to induce CCM lesions.
Sample collection. Neonatal pups at P13 were euthanized via carbon dioxide asphyxiation
and intra-cardiac perfused with 3 ml of 2% paraformaldehyde in PBS solution. Whole brains were
dissected and fixed 2.5% glutaraldehyde, 4% formaldehyde 0.1 M sodium phosphate buffer over-
night. On the following day, hindbrains were detached and washed with phosphate buffer before
contrast staining. Upon collection, a morphological image of each brain was taken as a record.
Contrast stains. Dissected hindbrains were incubated in 2% Osmium tetroxide (OsO4)
(C010, Proscitech) for approximately 24 hours under gentle agitation to promote sufficient
infusion of OsO4 into the hindbrain. Following the incubation, hindbrains were washed with
distilled water three times, ten minutes each. OsO4 is highly toxic; hence, the safety data sheet
was consulted and its handling procedures were strictly followed.
Sample packaging for micro-CT. OsO4 stained hindbrains were packaged in a 3 ml
syringe (DVR-3418, Terumo) with distilled water and a small sponge on each side to secure the
hindbrain and prevent it from moving during scan, and avoid direct contact with the hard
syringe wall.
Micro-CT scans
In the study, micro-CT scans were performed using an Xradia MicroXCT-400 system (Carl
Zeiss XRM, USA). The hindbrain packaged in a 3 ml syringe is mounted vertically on an alumi-
num holder in the MicroXCT. To acquire the tomographic data sets and to optimize micro-CT
scan for CCM lesions in mouse, different scanning parameters (exposure time, number of pro-
jections and beam conditions) were evaluated. The optimized scans were performed with con-
stant source conditions of 50kV and 10W.
To assess the post-scanned specimen, the radiographic datasets were imported into hard-
ware-based back projection reconstruction software supplied by Xradia, producing an image
series of 16-bit axial slices with slice-spacing equivalent to the pixel size for each sample (isotro-
pic voxels).
Micro-CT scans analysis
Reconstruction of the projections resulted in an axial stack saved as 16-bit grey-scale TIFF
images for further processing. Reconstruction parameters were kept constant for each scan to
provide uniform grey scale factors during analysis.
Fig 1. Overview of micro-CT imaging procedure.Mouse brains were dissected and fixed as described.
Following the fixation, only the hindbrain was stained with OsO4 as a contrast staining. Osmium stained
hindbrain was then scanned using micro-CT that produces series of radiographs. These radiographs were
reconstructed and AVIZO software was used to produce 3D image and quantify lesions in the hindbrain.
doi:10.1371/journal.pone.0160833.g001
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The reconstructed axial slice 3D datasets were visualized using commercially available 3D
rendering software, Avizo 3D image processing software (FEI Visualization Sciences Group).
The 3D axial datasets were imported into Avizo 3D, and image sequences were presented in
the axial (XY), frontal (YZ) and sagittal (XZ) planes. To obtain an approximately similar ana-
tomical plane of view, digital rotation of the reconstructed image was performed on some spec-
imens as required. The 3D reconstructions were ‘virtually sectioned’ into desired planes and
2D images from ortho-slices were captured showing the lesion distribution and brain
structures.
Raw image stacks from each scanned hindbrain were analyzed for lesion identification.
Lesions were identified and labeled using a greyscale intensity threshold and the shape of the
feature. A region-growing segmentation algorithm included with the software (Magic Wand)
was used to label individual lesions across multiple cross-sections.
Post-lesion labeling, the hindbrain image stack was isosurface (volume) rendered and over-
laid with the labeled lesions in Avizo. Finally, the 3D rendered and segmented hindbrain
model was cropped and rotated within the program to attain the desired spatially significant
view, thus highlighting the spatial relationship of the lesions and hindbrain. It is important to
point out that these changes were made post-lesion labeling, and lesion detection or visual pre-
sentation was not affected.
Statistical analysis
All the statistical analysis in the study was done using t-tests in Graphpad Prism statistical
software. Values are presented as mean±SE. Statistical significance was considered when
p-value0.05.
Results
Establishment of a micro-CT protocol to detect and analyze CCM lesions
in neonatal mice
Contrast-enhancing, whole mount staining methods has been used for micro-CT imaging of
soft tissues and mouse embryos [23,24], and OsO4 fixatives are widely used in Electron Micros-
copy to enhance contrast on ultrathin sections. Osmium preferentially binds to unsaturated
lipid [25,26]. The brain is an organ containing a high content of unsaturated lipids. We there-
fore reasoned that an osmium-based contrast enhancing method would be suitable for micro-
CT imaging of CCM lesions in brain.
To test whether osmium staining can be used to enhance contrast for micro-CT imaging of
neonatal brain, we stained neonatal mouse brains (P13) with OsO4 and subjected them to
high-resolution micro-CT imaging. Micro-CT is a highly technical and precise method which
allows optimization of a number of settings to produce optimal images to visualize target sam-
ple. Projection count and exposure time are critical settings, as variations in either are directly
proportional to the quality of the resulting image, however, they are also directly proportional
to the total scan time, an important variable for procedure cost and throughput. Therefore, we
have tested a number of different settings to determine the most optimal setting to scan mouse
hindbrains and achieve high-resolution images in the most efficient way.
We varied the number of projections and exposure times and compared image quality with
the duration of the scan. The image resolution (9.5μm/pixel) was kept constant throughout the
testing process. Initially, three settings were compared: 450 projection x 2second exposure time
(450proj x 2sec) (Fig 2A), 450proj x 10 sec (Fig 2B) and 1800proj x 4sec (Fig 2C). The durations
of the scans were approximately 1, 2 and 5 hours respectively. As expected, 1800proj x 4sec
Micro-CT Imaging of CCM
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setting produced the image with best clarity followed by 450proj x 10sec. However, 1800proj x
4sec setting required scanning time of five hours. Meanwhile 450proj x 10sec setting produced
Fig 2. Optimization of micro-CT imaging of CCM lesions in the neonatal mouse hindbrain.Different micro-CT settings were tested to identify optimal
images by which to detect CCM lesions. Initially, three different settings were tested: A) 450 projections x 2 seconds (1 hour scanning time), B) 450
projections x 10 seconds (2 hours) andC) 1800 projections x 4 seconds (5 hours). Furthermore, to determine the optimal beam voltage for highest
attenuation of osmium, three different energy levels were tested: D) 50keV, E) 65keV and F) 78keV.G) X-ray form factor graph of osmium and the distribution
of chosen energy level in the spectrum.H-I) Reconstructed images which detected CCM lesions (green arrows) (H and I) and distinguished blood-filled
lesions (red arrows) (I).
doi:10.1371/journal.pone.0160833.g002
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sufficient image quality to determine CCM lesions in the brain. 450proj x 2sec setting resulted
in unsatisfactory image quality, which was not suitable for determining CCM lesions.
Furthermore, three x-ray beam voltages were considered, taking into account osmium
attenuation (Fig 2D–2F). These beam voltages were chosen based on the x-ray form factor of
osmium (Fig 2G) obtained from National Institute of Standards and Technology (NIST) and
equipment limitations. It was determined that using 50 keV produced the most consistent
result in terms of penetration of the sample by the x-ray beam, minimisation of reconstruction
artifacts, and the avoidance of any false-positive identification of lesions as a result of soft-tis-
sue failing to adequately attenuate higher beam energies.
The number of projections and x-ray exposure time were further optimized with the goal of
a total scanning duration of approximately two hours. The 720proj x 3sec setting at 50keV pro-
duced the most satisfactory image (Fig 2D). From the scan, CCM lesions were easily distin-
guished (Fig 2H and 2I). Importantly the scan was able to easily distinguish blood filled versus
empty CCM lesions (Fig 2I). To further confirm data from 720proj x 3sec setting is not com-
promised by false negative detection, we compared CCM lesions (S1 Fig) identified from a sin-
gle brain sample from image datasets generated at 450proj x 3sec (~1.2hr), 720proj x 3sec
(~2hrs) and 1800proj x 3sec (~5hrs) setting. We found 92, 149 and 154 lesions from datasets of
450proj x 3sec, 720proj x 3sec and 1800proj x 3sec setting respectively (S1 Fig). Thus, at
720proj x 3sec setting, we were able to identify 96.8% of maximum lesion counts.
We conclude that the optimal study incorporates projection images that are integrated for 3
seconds every 0.25° over a full 180° rotation (720proj x 3sec) at 50keV for an efficient and satis-
factory condition to produce micro-CT images for CCM lesion assessment in mouse, with a
9.5μm pixel resolution, and a minimum feature size of approximately 25μm [27]. All the
micro-CT scans described further below were obtained using these conditions.
3-D Reconstruction of CCM lesions in mouse model
Utilizing the optimized micro-CT, we imaged CCM lesions in the hindbrains of Ccm1iECKO
mice (Fig 3A). Scanned x-ray images were reconstructed to produce 3D images of the mouse
brain, which allowed us to visualize entire lesions in the brain parenchyma (Fig 3B–3G and S1
Video) at different depths and orientations, and to assess structure and the 3-D location of
lesions in brain. Importantly, this image dataset can also be used for efficient and accurate
quantification of lesion sizes and lesion numbers.
Comparison of CCM lesions in Ccm1iECKO and Ccm2iECKOmice
Deleting Ccm1, Ccm2 or Ccm3 gene in neonatal mice confers CCM lesions in mouse brain
[13,15]. However, precise and reliable comparison of lesions (size and number) in mouse lack-
ing different Ccm genes have not been reported due to the lack of an efficient technique to eval-
uate and quantitatively compare global CCM lesion burden in brain. Hence, we have
compared lesions in 9 Ccm1iECKO mice from 4 different litters (Fig 4A–4C) and 5 Ccm2iECKO
mice from 4 different litters (Fig 4D–4F) mice. The location and structure of CCM lesions in
both models were highly similar (Fig 4B, 4C, 4E and 4F). Furthermore, to determine whether
the scan detects false positives (normal blood vessels), brains of littermate control mice (3
Ccm1fl/fl and 3 Ccm2fl/fl) treated with TMX were scanned (G-H). As a result, the scan failed to
detect any features that appear to be lesions or normal blood vessels suggesting that the scan is
optimal for detecting CCM lesions only. Lesion volume and lesion number between Ccm1iECKO
and Ccm2iECKO mice were also similar without statistical significance (Fig 4I and 4J). These
results suggest that both the Ccm1iECKO and Ccm2iECKO mouse models produce similar mor-
phological CCM lesions and lesion burden.
Micro-CT Imaging of CCM
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Mekk3 heterozygosity rescues CCM lesion conferred by induced loss of
Ccm2 gene in endothelial cells
MEKK3 directly interacts with CCM2 to transduce CCM signaling [10,28]. Recently, we have
shown that MEKK3 haploinsufficiency rescues CCM lesions in Ccm1iECKOmice [19]. However,
the rescue of CCM lesions in Ccm2iECKO mice by decreasedMekk3 gene dosage has not been
carefully assessed. We therefore investigated the role ofMekk3 gene dosage in CCM lesion for-
mation in Ccm2iECKO mice. As previously shown[13,15], deletion of Ccm2 gene caused CCM
lesion formation in mice (5 mice from 4 litters) (Fig 5A and 5C). Consistent with the protective
role ofMekk3 deletion in lesion formation in Ccm1iECKO mice[19], we found that loss of one
allele ofMekk3 gene was sufficient to prevent lesion formation in Ccm2iECKO mice (8 mice
from 4 litters) (Fig 5B, 5D and 5E). In summary, our studies demonstrate that elevated MEKK3
activity is causal for CCM lesion formation in the mouse models, and suggest that partial inhi-
bition of MEKK3 expression and/or activity is a promising therapeutic strategy to prevent and/
or treat CCM disease.
Discussion
Cerebral Cavernous Malformation (CCM) is also known as cavernoma or cavernous angioma
and is a common vascular malformation that affects 0.1–0.5% of individuals [1]. CCMs can
Fig 3. Three-dimensional images of mouse brain with CCM lesions. A)Macroscopic images of CCM lesions in the hindbrains ofCcm1iECKOmice.
B-G) 3-D visualization of CCM lesions at various levels and orientations in the hindbrain. CCM lesions were visualized with the reference to overall
hindbrain anatomy (B), from the back (C) and above (D) of hindbrain, and at different depth (E-G) inside hindbrain (red refers to CCM lesions).
doi:10.1371/journal.pone.0160833.g003
Micro-CT Imaging of CCM
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occur in sporadic or familial form. Patient prognosis is often unclear and lesions can rupture
unexpectedly to cause brain hemorrhage and neurological deficits. While surgical procedures
can be successful in some cases, there are currently no drugs or targeted therapeutics to prevent
or halt the progression of CCM disease.
Human genetic studies have demonstrated that mutations in any of three genes (CCM1,
CCM2 and CCM3) may cause CCM disease [2–6]. In the past decade, extensive work has been
done in cultured cells and model organisms to elucidate the role of CCM genes is regulating
endothelial cell function and cardiovascular development [7–11,29–32]. Animal models that
accurately reproduce human CCM conditions have been generated in past few years, with the
neonatal CCM gene deletion model providing the highest efficiency in forming lesions [12–
15]. These models are potentially invaluable tools to investigate the pathogenesis of CCM dis-
ease. However, their potential has been limited by the low throughput and non-quantitative
methods available to assess CCM lesion formation.
Currently, studies of CCM lesion burden rely primarily on histology-based methods. Partial
sectioning of lesion-bearing brain tissue provides a general impression of CCM burden, but is
not able to provide the accurate quantitation needed to compare the impact of genetic and
pharmacologic studies. While a complete serial section, histological staining and reconstruc-
tion is possible, it is highly time consuming and low yield. An MRI based method has also been
used to assess CCM lesions in adult mouse brains, but a long scan time (usually overnight for
each sample) is required to achieve a resolution threshold necessary to identify lesions. We
have tested MRI-based methods in neonatal mice, but could only detect the largest CCM
lesions and were unable to visualize lesions that were easily detectable using histologic methods
(not shown).
Micro-CT has the potential to image vascular lesions in the mouse brain. Microfil perfusion
based micro-CT method has been used to image cerebral vascular network in adult mice. Due
to the complexity of cerebral vascular system, perfusion is highly variable and dependent upon
the anatomy of the vessels and skill level of the operators. Vessels in certain areas in brain are
not consistently perfused, and special surgical procedures are needed to achieve consistent per-
fusion [33,34]. The brain vasculature in the neonatal CCMmouse model, and the sluggish or
even absent circulation in CCM lesions are important technical limitations of this method.
A second potential method to adopt micro-CT for CCM lesion imaging is contrast enhance-
ment with whole mount staining. After comparing various reagents used in micro-CT imaging
and electron microscopy, we chose OsO4, because of its preference in binding lipid [25] and
produces the most universal staining among various tissues according to previously published
data of mouse embryos [23].
In our recently established micro-CT method, the sample preparation is very straightfor-
ward and does not require highly specialized training or practice. Our method can provide con-
sistent high-resolution projections with a scan time of less than two hours. The coupling of
datasets from X-ray CT scanner and the 3-D Analysis software is a powerful tool to generate a
3-D global view of CCM lesions in brain. The morphology and distribution of lesion relevant
to brain anatomy can be easily observed and the total or individual lesion volume and lesion
number can be retrieved readily. Comparing with histology-based 3-D reconstruction, this
method is highly time and cost-effective. 3-D reconstruction from the image dataset of intact
whole-mount brain tissue produces more accurate 3-D representation.
Fig 4. Qualitative and quantitative comparison of CCM lesions inCcm1iECKO andCcm2iECKOmousemodels usingmicro-CT. A-H)
2-D graphs and rendered 3-D images of CCM lesions in Ccm1iECKO (A-C), Ccm2iECKO (D-F) and littermate control (Ccm1fl/fl andCcm2fl/fl)
(G-H) mice (red refers to CCM lesions). I-J) Quantitative comparison of CCM lesions volume (I) and number per brain (J) in Ccm1iECKO (n = 9
from 4 litters) andCcm2iECKOmice (n = 5 from 4 litters).
doi:10.1371/journal.pone.0160833.g004
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Fig 5. Mekk3 heterozygous deletion rescues CCM lesions in Ccm2iECKOmice.CCM lesions were qualitatively
analyzed by 3-D visualization. Representative Micro-CT scans (A) and 3-D projections (C) of Ccm2iECKOmouse and
rescued mice withMekk3 heterozygous deletion (Ccm2iECKO; Mekk3het) (B andD). Red refers to CCM lesions. E)
Quantitative comparison of CCM lesions volume in Ccm2iECKO (n = 5 from 4 litters) andCcm2iECKO;Mekk3het (n = 8
from 4 litters) mouse.
doi:10.1371/journal.pone.0160833.g005
Micro-CT Imaging of CCM
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We tested this method by comparing CCM lesions formed in Ccm1iECKO and Ccm2iECKO
animals. We found no significant difference in CCM lesion distribution, total volume and
lesion number. This is consistent with molecular studies suggesting CCM1 and CCM2 function
upstream in a same pathway, and human studies revealing a similar disease penetrance and
history for patients with mutations in these two genes[7,9,13,35].
We have recently reported that Mekk3 is recruited to and suppressed by the CCM complex
[10]. Loss of Ccm genes leads to increased activation of Mekk3 and its downstream transcrip-
tional targets. DecreasedMekk3 gene dosage prevented CCM lesion formation caused by Ccm1
deletion[19]. In this study, we extend this observation and report that deletion of one allele of
Mekk3 in the endothelium is also sufficient to prevent CCM lesion formation caused by Ccm2
deficiency. This further confirmsMekk3 as a common target effector of the CCM pathway.
Precise control of its activity is essential to maintain vessel integrity and prevent vessel malfor-
mation. Our studies provide additional evidence that inhibiting MEKK3 activation may be a
promising therapeutic strategy for CCM disease.
Our current method is only optimized for imaging fixed mouse brain samples ex vivo. How-
ever, our method also has the capacity to be used for other studies involving different organs,
and may serve as an exciting and novel tool for vascular malformation research in general. For
pre-clinical studies of CCM and other vascular diseases, it would be advantageous to monitor
lesion progression in live animals over a specified time-span. Therefore, the development of a
more advanced method to image CCM lesions in live mice would further propel research
efforts aimed at the development of new CCM therapeutics.
Supporting Information
S1 Fig. Verification of the optimized setting of micro-CT imaging of CCM lesions in the
neonatal mouse hindbrain. To verify the micro-CT setting of 720 projections x 3 seconds is
sufficient to accurately detect CCM lesions without false negatives; three different settings were
tested using a single sample: A-C) 2-D graph generated from scan settings at 450 projections x
3 seconds (A), 720 projections x 3 seconds (B) an 1800 projections x 3 seconds (C). Each scan
dataset was rendered and 3-D images were produced (D-F) and lesion numbers were calculated
(G). As a result, 720 projections x 3 seconds and 1800 projections x 3 seconds scan detected
similar lesion number suggesting that 720 projections x 3 seconds scan is sufficient and with
minimum negatives. However, 450 projections x 3 second scan failed to detect all the lesions.
(DOCX)
S1 Video. 3-D reconstruction of mouse brain with CCM lesions.
(MOV)
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